mRNA COVID Vaccine Dosing Intervals May Be Extended To Mitigate Myocarditis Risk

While data suggests higher risk of myocarditis in young males receiving Moderna’s vaccine, US CDC advisory committee did not consider preferential recommendation. ACIP voted to recommend Spikevax for those 18 years and older following full FDA approval.

Spikevax and Comirnaty
CDC advisory committee considers myocarditis risk with Moderna and Pfizer's mRNA vaccines • Source: Alamy

The US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices supports extending the interval between the first and second doses of mRNA COVID-19 vaccines to eight weeks in order to mitigate the risk of myocarditis.

The committee did not vote on whether to change the dosing interval, but members agreed that it would be beneficial....

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet